New York, New York 10021


Purpose:

The purpose of this study is to evaluate patients with cirrhosis of the liver and renal failure and determine if the administration of rifaximin as compared to lactulose is associated with less frequent and/or slower progression to severe hepatic encephalopathy. If one is associated with lower blood ammonia levels. And, if one is associated with lower breath hydrogen and methane levels.


Criteria:

Inclusion Criteria: - cirrhosis of liver of any etiology - progressive renal failure - stage 0-2 hepatic encephalopathy Exclusion Criteria: - pregnant women


NCT ID:

NCT00748904


Primary Contact:

Samuel Sigal, MD
Phone: 212-746-4129
Email: shs2015@nyp.org


Backup Contact:

Email: amy.tilara@gmail.com
Amy Tilara, MD
Phone: 646-713-7284


Location Contact:

New York, New York 10021
United States

Samuel Sigal, MD
Phone: 212-746-4129
Email: shs2015@nyp.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.